Clinical Trials · NCT02152371
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 300
- Start date
- May 2014
- Locations
- 40 sites, 7 countries
- Primary endpoint
- Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)